Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ACA Countdown: Details Emerging On Exchanges, Medicaid Expansion

This article was originally published in The Pink Sheet Daily

Executive Summary

Open enrollment in state exchange plans kicks off Oct. 1 and expanded Medicaid eligibility Jan. 1, and many states offer a preliminary view of how coverage will play out under the Affordable Care Act in 2014.

You may also be interested in...

Rx Spending Expected To Grow 5% In First Year of Expanded Health Coverage, CMS Predicts

CMS projects the year-over-year growth in retail prescription drug spending to jump from a negative to flat growth in 2012 and 2013 to more than 5% in 2014 and nearly 7% in 2015, largely due to expanded health care coverage under the Affordable Care Act.

Biopharma Sizes Up The Affordable Care Act: Buyer’s Remorse Or Winner’s Curse?

Three years into the ACA, the biopharma industry takes stock of its near-term wins and losses as the law’s critical expanded insurance coverage takes effect beginning in 2014. Pharma still isn’t sure whether the increase in covered lives from the exchanges will boost prescription sales enough to offset the rebates, taxes, and fees it agreed to pay out, or what kind of patients constitute this new market.

Ulta Beauty Leadership Offers 2023 Holiday Outlook, AI Update In Q3 Earnings Call

The US’ biggest beauty retailer is targeting fiscal 2023 net sales between $11.1bn and $11.15bn, with comparable sales growth of 5% to 5.5%, and is optimistic about 2024 and longer-term strategies. CEO David Kimbell addressed analyst questions on the 2023 holiday season, AI and other points of interest during the firm’s third-quarter earnings call.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts